GlassScriptPhysician profile
Barbara S Frasher
NPI 1396182911
$1,843.40
in general payments reported to CMS, 2019-2025
25 companies · $313 in 2025
The $313 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $584 · 2023: $204 · 2024: $257 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $774.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $774.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $302.40 | 2021-2025 | |
| Astellas Pharma US INC | $241.76 | 2021-2025 | Xtandi, Myrbetriq |
| Urovant Sciences INC | $195.63 | 2022 | |
| Coloplast Corp | $151.88 | 2021 | |
| Janssen Biotech, INC. | $140.26 | 2021-2024 | Erleada |
| Myovant Sciences INC. | $126.08 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $106.48 | 2021-2023 | Provenge |
| Sumitomo Pharma America, INC. | $86.42 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $56.86 | 2024-2025 | |
| Ambu INC. | $49.37 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $41.21 | 2021-2022 | |
| Accord Healthcare, INC. | $36.66 | 2022-2023 | |
| Olympus America INC. | $34.74 | 2021-2022 | |
| Boston Scientific Corporation | $33.08 | 2024-2025 | Spaceoar Vue System - 10ml, Rezum Generator |
| Immunitybio, INC. | $29.87 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $27.70 | 2021 | |
| Urogen Pharma, INC. | $26.97 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.43 | 2024 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $23.08 | 2025 | |
| Azurity Pharmaceuticals, INC. | $22.21 | 2025 | Azmiro |
| Genzyme Corporation | $20.91 | 2023 | |
| Alnylam Pharmaceuticals INC. | $19.48 | 2021 | |
| Myriad Genetic Laboratories, INC. | $17.92 | 2023 | Prolaris |
| Axonics, INC. | $16.62 | 2022 | |
| Laborie Medical Technologies Corp. | $12.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Frasher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.